| Autor: |
Al Mamari, Naama, Al Zawawi, Nabighah, Khayat, Suhaib, Badeghiesh, Ahmed, Son, Weon-Young, Dahan, Michael H. |
| Předmět: |
|
| Zdroj: |
Journal of Assisted Reproduction & Genetics; Nov2019, Vol. 36 Issue 11, p2307-2313, 7p |
| Abstrakt: |
Purpose: The objective of this study is to identify the pregnancy outcomes based on day-16 β-hCG level assessed with modern assays, in fresh single embryo transfers. Methods: A retrospective cohort study at a single academic center between 2013 and 2017. A total of 1076 pregnancies were included. Results: Pregnancies were divided into 10% groupings of 107–108 patients each. The 10 groups did not differ for baseline characteristics. There was no difference on outcomes based on cleavage or blastocyst transfer. At a serum β-hCG level of 103 ± 13 (range 74–135), 50% had a biochemical loss. Biochemical pregnancy losses remained 21% at serum β-hCG range (136–197). It was only once serum β-hCG level reached 199–252 that the probability of a biochemical pregnancy loss was 12%. Interestingly, if a clinical pregnancy is present even at low day-16 serum β-hCG levels, the likelihood of live birth is approximately 50%. This maximizes to 75% when the serum β-hCG level was at least 253 IU/L. The relationship between serum day-16 β-hCG levels and clinical pregnancy or live birth is quite strong with correlation coefficients above 0.8 which accounted for more than 75% of the variability in outcomes in both cases. Receiver operator curves determined that the cut-off for a clinical pregnancy was 190 and for live birth, it was 213 IU/L. Conclusion: An increase in the serum β-hCG levels at which to expect a reassuring outcome is required based on modern assays, as compared with the old cut-off levels. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink